Salma Zemrani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Salma Zemrani has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Bouchra Amine
Rheumatology Department A, El Ayachi Hospital, CHU Rabat-Salé, Rabat, Morocco
4 shared publications - Rachid Bahiri
Rheumatology A Department, El Ayachi Hospital, CHU Rabat-Salé, Salé, Morocco
4 shared publications Bouchra Amine
Department of Rheumatology A, El Ayachi Hospital, Ibn Sina University Hospital, Salé, Morocco
3 shared publications- Imane El Binoune
Rheumatology Department A, El Ayachi Hospital, CHU Rabat-Salé, Rabat, Morocco
3 shared publications Rachid Bahiri
Department of Rheumatology A, El Ayachi Hospital, Ibn Sina University Hospital, Salé, Morocco
3 shared publicationsSamira Rostom
Department of Rheumatology A, El Ayachi Hospital, Ibn Sina University Hospital, Salé, Morocco
3 shared publications
Latest Publications
- 28 September 2026
- Published by Bentham Science Publishers Ltd. in Current Rheumatology Reviews
- Vol. 22, 1-11
Multimorbidity and Hospital-related Outcomes in Patients with Rheumatoid Arthritis: A Cross-sectional Study
Introduction: Multimorbidity is frequent in rheumatoid arthritis (RA) and is associated with increased mortality, impaired quality of life, and complex clinical management. However, its association with hospitalization characteristics, particularly hospital length of stay and reasons for admission, remains insufficiently characterized. Methods: We conducted a five-month cross-sectional study (February to July 2024) in a tertiary university hospital, including adult patients diagnosed with rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria. Multimorbidity was defined as the presence of at least two chronic comorbid conditions (CHCs), and patients were stratified into two categories: multimorbid (MMG) and non-multimorbid (N-MMG) groups. Data collected included demographic characteristics, clinical features, laboratory parameters, and imaging findings. Functional impairment was assessed using the Health Assessment Questionnaire (HAQ). Results: The study included 126 individuals with a mean age of 56.6 ± 13.4 years, of whom 84.9% were female. Multimorbidity was present in 52.4% of cases. Patients in the MMG were significantly older than those in the N-MMG (62.1 ± 9.9 vs 50.5 ± 14.2 years, p < 0.001). They also had significantly higher disease activity (DAS28, p < 0.001) and more impaired functional status as measured by HAQ (p < 0.001). Length of hospital stay was significantly longer in the multimorbid group. A hospital stay of 14 days or more was observed in 31% of MMG patients compared with 10.3% in the N-MMG cohort. Multivariate logistic regression analysis revealed that increasing age (OR = 1.11, 95% CI: 1.05-1.17, p < 0.001) and current corticosteroid use (OR = 4.73, 95% CI: 1.73-12.95, p = 0.002) were independently associated with multimorbidity. In addition, multimorbidity remained independently associated with prolonged hospitalization after adjustment for age, disease duration, disease activity, and corticosteroid use (adjusted OR = 3.42, 95% CI: 1.36-8.60; p = 0.009). Discussion: In this study, multimorbidity was associated with greater clinical complexity among hospitalized patients with RA and with less favorable hospital-related outcomes, particularly longer hospitalization duration. The higher disease activity and poorer functional status observed among multimorbid patients may partly explain the longer hospital stays observed. Conclusion: Our findings indicate that multimorbidity is associated with a more complex clinical profile in hospitalized patients with rheumatoid arthritis and with poorer hospital-related outcomes, particularly prolonged length of stay. These associations may partly reflect the higher disease activity and greater functional impairment observed among multimorbid patients.
- 28 September 2026
- Published by Bentham Science Publishers Ltd. in Current Rheumatology Reviews
- Vol. 22, 1-11
Multimorbidity and Hospital-related Outcomes in Patients with Rheumatoid Arthritis: A Cross-sectional Study
Introduction: Multimorbidity is frequent in rheumatoid arthritis (RA) and is associated with increased mortality, impaired quality of life, and complex clinical management. However, its association with hospitalization characteristics, particularly hospital length of stay and reasons for admission, remains insufficiently characterized. Methods: We conducted a five-month cross-sectional study (February to July 2024) in a tertiary university hospital, including adult patients diagnosed with rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria. Multimorbidity was defined as the presence of at least two chronic comorbid conditions (CHCs), and patients were stratified into two categories: multimorbid (MMG) and non-multimorbid (N-MMG) groups. Data collected included demographic characteristics, clinical features, laboratory parameters, and imaging findings. Functional impairment was assessed using the Health Assessment Questionnaire (HAQ). Results: The study included 126 individuals with a mean age of 56.6 ± 13.4 years, of whom 84.9% were female. Multimorbidity was present in 52.4% of cases. Patients in the MMG were significantly older than those in the N-MMG (62.1 ± 9.9 vs 50.5 ± 14.2 years, p < 0.001). They also had significantly higher disease activity (DAS28, p < 0.001) and more impaired functional status as measured by HAQ (p < 0.001). Length of hospital stay was significantly longer in the multimorbid group. A hospital stay of 14 days or more was observed in 31% of MMG patients compared with 10.3% in the N-MMG cohort. Multivariate logistic regression analysis revealed that increasing age (OR = 1.11, 95% CI: 1.05-1.17, p < 0.001) and current corticosteroid use (OR = 4.73, 95% CI: 1.73-12.95, p = 0.002) were independently associated with multimorbidity. In addition, multimorbidity remained independently associated with prolonged hospitalization after adjustment for age, disease duration, disease activity, and corticosteroid use (adjusted OR = 3.42, 95% CI: 1.36-8.60; p = 0.009). Discussion: In this study, multimorbidity was associated with greater clinical complexity among hospitalized patients with RA and with less favorable hospital-related outcomes, particularly longer hospitalization duration. The higher disease activity and poorer functional status observed among multimorbid patients may partly explain the longer hospital stays observed. Conclusion: Our findings indicate that multimorbidity is associated with a more complex clinical profile in hospitalized patients with rheumatoid arthritis and with poorer hospital-related outcomes, particularly prolonged length of stay. These associations may partly reflect the higher disease activity and greater functional impairment observed among multimorbid patients.
- Open Access
- 12 July 2026
- Published by Springer Nature
- p. 171-188
Rheumatic Diseases in Morocco
Morocco has approximately 400 registered rheumatologists serving a population of 37.7 million, corresponding to a low workforce density of about one rheumatologist per 100,000 inhabitants. This shortage is particularly concerning in the context of population aging and the anticipated increase in the burden of rheumatic diseases. The Moroccan health system includes both public and private sectors, with the private sector expanding rapidly, particularly in regions such as Casablanca-Settat and Rabat-Salé-Kénitra. Rheumatology practice is represented nationally by the Moroccan Society of Rheumatology (SMR), which brings together specialists and practitioners interested in musculoskeletal diseases. The SMR plays a central role in advancing clinical practice, education, research, and advocacy and has progressively strengthened its organizational structure and strategic capacity. Key initiatives include training programs in musculoskeletal ultrasound; the Moroccan Registry of Biological Therapies in Rheumatoid Diseases (RBSMR), one of the earliest registries of its kind in Africa; patient education programs to improve long-term disease management; and national public awareness campaigns. Despite substantial progress over the past two decades, important challenges remain. Priority areas for future development include increasing the rheumatology workforce, establishing centers of excellence, and expanding research programs tailored to the specific epidemiological and health care needs of the Moroccan population.
- 12 July 2026
- Published by Springer Nature
- p. 171-188
Open AccessRheumatic Diseases in Morocco
Morocco has approximately 400 registered rheumatologists serving a population of 37.7 million, corresponding to a low workforce density of about one rheumatologist per 100,000 inhabitants. This shortage is particularly concerning in the context of population aging and the anticipated increase in the burden of rheumatic diseases. The Moroccan health system includes both public and private sectors, with the private sector expanding rapidly, particularly in regions such as Casablanca-Settat and Rabat-Salé-Kénitra. Rheumatology practice is represented nationally by the Moroccan Society of Rheumatology (SMR), which brings together specialists and practitioners interested in musculoskeletal diseases. The SMR plays a central role in advancing clinical practice, education, research, and advocacy and has progressively strengthened its organizational structure and strategic capacity. Key initiatives include training programs in musculoskeletal ultrasound; the Moroccan Registry of Biological Therapies in Rheumatoid Diseases (RBSMR), one of the earliest registries of its kind in Africa; patient education programs to improve long-term disease management; and national public awareness campaigns. Despite substantial progress over the past two decades, important challenges remain. Priority areas for future development include increasing the rheumatology workforce, establishing centers of excellence, and expanding research programs tailored to the specific epidemiological and health care needs of the Moroccan population.
- Open Access
- 1 December 2025
- Published by Springer Nature in BMC Rheumatology
- Vol. 10 (1)
Use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis receiving biotherapy and associated factors: a prospective cohort study
The objectives of this study were to evaluate NSAID use over time in patients with axial spondyloarthritis (axSpA) receiving biologic therapy, to determine
- 1 December 2025
- Published by Springer Nature in BMC Rheumatology
- Vol. 10 (1)
Open AccessUse of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis receiving biotherapy and associated factors: a prospective cohort study
The objectives of this study were to evaluate NSAID use over time in patients with axial spondyloarthritis (axSpA) receiving biologic therapy, to determine
- Open Access
- 20 June 2025
- Published by Termedia Sp. z.o.o. in Rheumatology
- Vol. 63 (3) , 166-173
Insights into diagnosis and treatment of fibromyalgia among Moroccan rheumatologists: a cross sectional online survey
Introduction: This study outlines the diagnostic and therapeutic approaches – both pharmacological and non-pharmacological – used by Moroccan rheumatologists in managing fibromyalgia (FM). It also addresses other key aspects, such as assessing the psychosocial context of patients and referring them to other medical specialties.Material and methods: A descriptive cross-sectional study was conducted using a survey designed to assess the management approach of Moroccan rheumatologists towards FM. The survey was carried out anonymously.Results: Out of 275 rheumatologists, 140 responded to the questionnaire (with a total of approximately 450 rheumatologists in Morocco). Ninety-nine percent (n = 139) reported encountering FM patients in their practice. Diagnosis of FM was predominantly based on clinical assessment without a scoring system (n = 66; 47%), while 20.7% (n = 29) used the FIRST score. A substantial proportion (70%) of participants requested biological and imaging workups despite apparent FM, with 92% (n = 129) opting for an inflammatory workup. Regarding the treatment aspect, paracetamol was the first-line analgesic prescribed by 58% (n = 81), followed by tramadol (n = 43; 30.9%). Pregabalin was the most commonly prescribed first-line treatment (n = 37; 27.4%), with antidepressants being the second-line choice in 35.8% (n = 42). Non-pharmacological treatments such as physical therapy, therapeutic education, and psychotherapy were the most highly recommended. Nearly all rheumatologists (n = 131; 93.6%) emphasized the need for multidisciplinary management for FM patients, often referring them to psychiatrists either alone or in conjunction with other specialists.Conclusions: Diagnosing and treating FM presents significant challenges. This survey sheds light on the diverse approaches adopted by Moroccan rheumatologists towards managing patients with FM, emphasizing the importance of multidisciplinary care in addressing the complex needs of these patients.
- 20 June 2025
- Published by Termedia Sp. z.o.o. in Rheumatology
- Vol. 63 (3) , 166-173
Open AccessInsights into diagnosis and treatment of fibromyalgia among Moroccan rheumatologists: a cross sectional online survey
Introduction: This study outlines the diagnostic and therapeutic approaches – both pharmacological and non-pharmacological – used by Moroccan rheumatologists in managing fibromyalgia (FM). It also addresses other key aspects, such as assessing the psychosocial context of patients and referring them to other medical specialties.Material and methods: A descriptive cross-sectional study was conducted using a survey designed to assess the management approach of Moroccan rheumatologists towards FM. The survey was carried out anonymously.Results: Out of 275 rheumatologists, 140 responded to the questionnaire (with a total of approximately 450 rheumatologists in Morocco). Ninety-nine percent (n = 139) reported encountering FM patients in their practice. Diagnosis of FM was predominantly based on clinical assessment without a scoring system (n = 66; 47%), while 20.7% (n = 29) used the FIRST score. A substantial proportion (70%) of participants requested biological and imaging workups despite apparent FM, with 92% (n = 129) opting for an inflammatory workup. Regarding the treatment aspect, paracetamol was the first-line analgesic prescribed by 58% (n = 81), followed by tramadol (n = 43; 30.9%). Pregabalin was the most commonly prescribed first-line treatment (n = 37; 27.4%), with antidepressants being the second-line choice in 35.8% (n = 42). Non-pharmacological treatments such as physical therapy, therapeutic education, and psychotherapy were the most highly recommended. Nearly all rheumatologists (n = 131; 93.6%) emphasized the need for multidisciplinary management for FM patients, often referring them to psychiatrists either alone or in conjunction with other specialists.Conclusions: Diagnosing and treating FM presents significant challenges. This survey sheds light on the diverse approaches adopted by Moroccan rheumatologists towards managing patients with FM, emphasizing the importance of multidisciplinary care in addressing the complex needs of these patients.
- Open Access
- 1 March 2025
- Published by Convin SA in Mediterranean Journal of Rheumatology
- Vol. 36 (1) , 79-85
Tuberculosis Under Biotherapy in Patients with Spondyloarthritis: Data from the Moroccan Biotherapy Registry (RBSMR) during 3 Years of Follow Up
Biologics agents may lead to a significant risk of infection, including tuberculosis, particularly in endemic countries. This study aims to determine the incidence and characteristics of active tuberculosis in spondyloarthritis patients undergoing biotherapies and estimate the rate of reactivation of latent tuberculosis infection (LTBI). A prospective multicentre study was conducted based on 3-year data from the Moroccan Register of Biotherapies (RBSMR). We determined the incidence rate of tuberculosis during follow-up and performed a comparison with patients in whom tuberculosis was not detected. Screening for LTBI prior to the initiation of biotherapy was analysed, and the reactivation rate was determined at the 3-year follow-up. 194 patients with SpA were included. 98.8% of the patients received TNF-inhibitors, and 6.6% had a history of treated tuberculosis infection. After 3 years of follow-up, 10 cases of active tuberculosis were recorded with an incidence of 17/1000 patient-years. All of these patients were on TNF-inhibitors. diabetes was significantly higher in patients with active tuberculosis (P=0.02), as was the prior use of at least two TNF-inhibitors (P=0.03). Before initiating biotherapy, 22.6% of individuals were found to have LTBI and received chemoprophylaxis. After a 3-year follow-up, only 2 (4.5%) cases of active TB were noted in patients previously treated for LTBI whereas the other 8 cases had negative screening. This study suggests that patients undergoing biotherapy, particularly TNF-inhibitors have a higher incidence of active tuberculosis compared to the general population. Rheumatologists should be aware of both reactivation LTBI and de novo tuberculosis.
- 1 March 2025
- Published by Convin SA in Mediterranean Journal of Rheumatology
- Vol. 36 (1) , 79-85
Open AccessTuberculosis Under Biotherapy in Patients with Spondyloarthritis: Data from the Moroccan Biotherapy Registry (RBSMR) during 3 Years of Follow Up
Biologics agents may lead to a significant risk of infection, including tuberculosis, particularly in endemic countries. This study aims to determine the incidence and characteristics of active tuberculosis in spondyloarthritis patients undergoing biotherapies and estimate the rate of reactivation of latent tuberculosis infection (LTBI). A prospective multicentre study was conducted based on 3-year data from the Moroccan Register of Biotherapies (RBSMR). We determined the incidence rate of tuberculosis during follow-up and performed a comparison with patients in whom tuberculosis was not detected. Screening for LTBI prior to the initiation of biotherapy was analysed, and the reactivation rate was determined at the 3-year follow-up. 194 patients with SpA were included. 98.8% of the patients received TNF-inhibitors, and 6.6% had a history of treated tuberculosis infection. After 3 years of follow-up, 10 cases of active tuberculosis were recorded with an incidence of 17/1000 patient-years. All of these patients were on TNF-inhibitors. diabetes was significantly higher in patients with active tuberculosis (P=0.02), as was the prior use of at least two TNF-inhibitors (P=0.03). Before initiating biotherapy, 22.6% of individuals were found to have LTBI and received chemoprophylaxis. After a 3-year follow-up, only 2 (4.5%) cases of active TB were noted in patients previously treated for LTBI whereas the other 8 cases had negative screening. This study suggests that patients undergoing biotherapy, particularly TNF-inhibitors have a higher incidence of active tuberculosis compared to the general population. Rheumatologists should be aware of both reactivation LTBI and de novo tuberculosis.
- Open Access
- 1 December 2024
- Published by Convin SA in Mediterranean Journal of Rheumatology
- Vol. 35 (Suppl 3) , 549-556
Difficult-to-Treat Spondyloarthritis in Morocco: A Real-World Study
High biologic requirement in inflammatory rheumatic diseases (IRD) may indicate a difficult to treat (D2T) condition. In axial spondyloarthritis (axSpA), a consensual definition for this concept is still lacking. Our objectives are to identify the prevalence and characteristics of multiswitcher patients with axSpA, and to analyse the number and reasons for switches. This is a longitudinal observational study including patients treated with biologic agents for axSpA. We propose to define D2T patients as those who required more than 2 b/tsDMARD. Patients who did not fulfil this definition were used as controls. The prevalence of multiswitchers was calculated, and characteristics were compared between the two groups. The number and reasons for switches were analysed in the D2T group. 124 patients were included. The prevalence of multiswitchers was 24.19%. There were no significant differences between the two groups in the age, sex, and comorbidities. D2T patients have more arthritis (p=0.01), and fibromyalgia (p=0.04), and higher disease activity before initiating biotherapy, (BASDAI:p=0.04), (ASDAS:p=0.04). Additionally, the time from diagnosis to the first use of biologic was longer (p=0.04). In the multivariate analysis, the D2T condition was found to be associated with fibromyalgia (p=0.01). Among this group, the prevalence of those treated with 3, 4, and 5 b/tsDMARD was 86%, 9%, and 5%, respectively, the primary and secondary failures were the most common reasons for switching. We suggest that D2T-axSpA present several characteristics. Identification of this category in large studies is necessary to establish a consensus definition.
- 1 December 2024
- Published by Convin SA in Mediterranean Journal of Rheumatology
- Vol. 35 (Suppl 3) , 549-556
Open AccessDifficult-to-Treat Spondyloarthritis in Morocco: A Real-World Study
High biologic requirement in inflammatory rheumatic diseases (IRD) may indicate a difficult to treat (D2T) condition. In axial spondyloarthritis (axSpA), a consensual definition for this concept is still lacking. Our objectives are to identify the prevalence and characteristics of multiswitcher patients with axSpA, and to analyse the number and reasons for switches. This is a longitudinal observational study including patients treated with biologic agents for axSpA. We propose to define D2T patients as those who required more than 2 b/tsDMARD. Patients who did not fulfil this definition were used as controls. The prevalence of multiswitchers was calculated, and characteristics were compared between the two groups. The number and reasons for switches were analysed in the D2T group. 124 patients were included. The prevalence of multiswitchers was 24.19%. There were no significant differences between the two groups in the age, sex, and comorbidities. D2T patients have more arthritis (p=0.01), and fibromyalgia (p=0.04), and higher disease activity before initiating biotherapy, (BASDAI:p=0.04), (ASDAS:p=0.04). Additionally, the time from diagnosis to the first use of biologic was longer (p=0.04). In the multivariate analysis, the D2T condition was found to be associated with fibromyalgia (p=0.01). Among this group, the prevalence of those treated with 3, 4, and 5 b/tsDMARD was 86%, 9%, and 5%, respectively, the primary and secondary failures were the most common reasons for switching. We suggest that D2T-axSpA present several characteristics. Identification of this category in large studies is necessary to establish a consensus definition.
- 9 November 2024
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 19 (1) , 1-11
Dietary recommendations of the Moroccan Society of Rheumatology (SMR) for patients with ostéosarcopenia
- 9 November 2024
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 19 (1) , 1-11
Dietary recommendations of the Moroccan Society of Rheumatology (SMR) for patients with ostéosarcopenia
- 25 September 2024
- Published by Elsevier in Joint Bone Spine
- Vol. 92 (1) , 105779
Dacryoadenitis occurring during treatment with etanercept
- 25 September 2024
- Published by Elsevier in Joint Bone Spine
- Vol. 92 (1) , 105779
Dacryoadenitis occurring during treatment with etanercept